Hosted on MSN10d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show ...
NBC Los Angeles6d
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...
Novo Nordisk: Not As Bullish As Many
Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...
Novo Nordisk’s Worst Month Since 2002 Shows Growth Concerns
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...
Novo Nordisk shares post the biggest monthly decline since 2002
Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...
NBC Washington10d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...